Mavacamten | USP/EP-Certified Myosin Modulator | Bulk API for Hypertrophic Cardiomyopathy
Google Keywords: Mavacamten bulk supplier, cardiac myosin inhibitor API, HCM treatment, USP-certified cardiovascular drug
🌟 Product Overview
Mavacamten (CAS 1642288-47-8) is a selective small-molecule modulator of cardiac myosin, designed to treat hypertrophic cardiomyopathy (HCM) by reducing excessive myocardial contractility. It targets the β-cardiac myosin-S1 ATPase pathway to normalize sarcomere function, improving cardiac output and symptom management12. Approved for clinical use, it is pivotal in both therapeutic and cardiovascular research applications16.
✔️ Key Advantages
High Purity: ≥99% HPLC purity compliant with USP/EP standards12.
Bulk Customization: Available in 1kg–25kg batches with batch-specific COA, MSDS, and stability data24.
Solubility: White crystalline powder soluble in DMSO (≥20 mg/ml) for preclinical formulations23.
🏥 Applications
Hypertrophic Cardiomyopathy: First-line therapy for reducing ventricular hypertrophy and improving cardiac function12.
Cardiovascular Drug Development: Key reference standard for HCM drug discovery36.
Research: Mechanistic studies on sarcomere dynamics and myocardial contractility regulation37.
📜 Quality Compliance
Certified under USP/EP guidelines with heavy metals <20ppm and residual solvents <10ppm24.
Stability tested for 24 months at -20°C in airtight, light-protected packaging24.
📈 Market Trends
The global HCM treatment market is projected to grow at 8.2% CAGR (2025-2030), driven by rising demand for precision therapies like Mavacamten. Its targeted mechanism positions it as a cornerstone in cardiovascular pharmacotherapy13.
China
